Loading stock data…
Forte Biosciences, Inc. (FBRX)
$21.32
Forte Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Forte Biosciences, Inc. in the Healthcare sector is trading at $21.32 with a market capitalization of $437M. Wall Street consensus targets $63.75 (4 analysts), implying a +199.0% move over the next 12 months. The stock is currently 40% below its 52-week high of $35.80, remaining 5.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 85 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +199.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 85 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.44M↑ | -$24.57M↓ | -$18.38M↓ | -$11.58M↑ | -$16.12M |
| Net Income | -$22.14M↑ | -$24.79M↓ | -$17.68M↓ | -$11.25M↑ | -$15.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and aut...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$436.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-180.18%
Volume
Today's trading volume
-
Recent News
One Forte Biosciences Insider Raised Stake By 30% In Previous Year
From what we can see, insiders were net buyers in Forte Biosciences, Inc.'s ( NASDAQ:FBRX ) during the past 12 months...
Top Midday Gainers
Ares Management (ARES) on Thursday agreed to acquire real estate investment trust Whitestone REIT (W
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Forte Biosciences...
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock
Investors who take an interest in Forte Biosciences, Inc. ( NASDAQ:FBRX ) should definitely note that the Chief...